ResearcherUniversity of California, San FranciscoNo recent work listed
Julia C. Carnevale
Matched on ORCID iD 0000-0001-9410-7148; OpenAlex author ID A5031288846. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 10
2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: none · 2021: 2 papers · 2022: 1 paper
Papers 6
- The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Co-author DOI 10.1097/mpa.0000000000002021↗
- Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Co-author DOI 10.1002/onco.13968↗
- Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. Co-author DOI 10.2217/imt-2021-0008↗
- Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. First author DOI 10.1007/s10689-018-0106-2↗
- MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. Co-author DOI 10.2217/fon.15.333↗
- Assessing the Significance of BRCA1 and BRCA2 Mutations in Pancreatic Cancer. Co-author DOI 10.1200/jco.2015.61.6961↗
Closest collaborators
The 10 strongest of 10 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Andrew H. Ko · 5 shared papers, 2016–2022 · strength 0.69
- Paper The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. DOI 10.1097/mpa.0000000000002021↗
- Paper Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. DOI 10.2217/imt-2021-0008↗
- Paper MM-398 (nanoliposomal irinotecan): emergence of a novel therapy for the treatment of advanced pancreatic cancer. DOI 10.2217/fon.15.333↗
- Evan Justin Walker · 4 shared papers, 2019–2022 · strength 0.57
- Paper The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. DOI 10.1097/mpa.0000000000002021↗
- Paper Durable response after immune checkpoint inhibitor-related diabetes in mismatch repair-deficient pancreatic cancer. DOI 10.2217/imt-2021-0008↗
- Paper Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreat… DOI 10.1002/onco.13968↗
- Margaret A. Tempero · 3 shared papers, 2019–2022 · strength 0.40
- Paper The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. DOI 10.1097/mpa.0000000000002021↗
- Paper Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreat… DOI 10.1002/onco.13968↗
- Paper Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. DOI 10.1007/s10689-018-0106-2↗
- Pelin Cinar · 2 shared papers, 2021–2022 · strength 0.30
- Eric Andrew Collisson · 2 shared papers, 2019–2021 · strength 0.22
- Paper Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreat… DOI 10.1002/onco.13968↗
- Paper Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. DOI 10.1007/s10689-018-0106-2↗
- Eric Andrew Collisson · 1 shared paper, 2022 · strength 0.17
- George Albert Fisher · 1 shared paper, 2021 · strength 0.17
- Erica S. Tsang · 1 shared paper, 2021 · strength 0.17
- Mallika Dhawan · 1 shared paper, 2021 · strength 0.12
- Alan Ashworth · 1 shared paper, 2015 · strength 0.11
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.